Application of mFOLFOX Regimen Combined with Bevacizumab in First-line Treatment of Metastatic Colorectal Cancer
To investigate the application value of mFOLFOX regimen combined with bevacizumab in the first-line treatment of meta-static colorectal cancer(mCRC),a total of 120 patients with metastatic colorectal cancer admitted to the hospital from May 2018 to May 2021 were included and randomly divided into bevacizumab group and control group,60 cases in each group.The control group was only treated with mFOLFOX regimen(mFOLFOX6 regimen was used this time),and the bevacizumab group was treated with mFOLFOX6 regimen combined with bevacizumab.After 3 months of treatment,the short-term efficacy of the two groups was com-pared.Before and after 3 months of treatment,the apoptosis index of tumor cells and serum carcinoembryonic antigen(CEA),carbo-hydrate antigen 199(CA199),carbohydrate antigen 72-4(CA72-4),vascular endothelial growth factor(VEGF),cyclooxygenase-2(COX-2),matrix metalloproteinase-9(MMP-9),Apurinic apyrimidinic endonuclease 1(APE)were compared between the two groups.Protein and S100 calcium-binding protein A9(S100A9)levels,and the incidence of toxic and side effects in the two groups were recorded.Patients were followed up from the first day of treatment to May 2022,and the median survival time was compared between the two groups.The disease control rate of the bevacizumab group(86.67％)was higher than that of the control group(71.67％)(P＜0.05).The levels of serum CEA,CA199 and CA72-4 in the two groups after treatment were lower than those before treatment,and the bevacizumab group was lower than the control group(P＜0.05).The apoptosis index of tumor cells in the two groups after treatment was higher than that before treatment,and the bevacizumab group was higher than that in the control group(P＜0.05).The serum levels of VEGF,COX-2,MMP-9,APE1 protein and S100A9 in the two groups after treatment were lower than those before treatment,and those in bevacizumab group were lower than those in control group(P＜0.05).There were no differences in the incidence of liver damage,thrombocytopenia,peripheral neurotoxicity,nausea and vomiting,leukopenia,proteinuria and hypertension between the two groups(P＞0.05).The median survival time of bevacizumab group(20 months)was longer than that of control group(14 months)(P＜0.05).mFOLFOX6 regimen combined with bevacizumab can effectively improve the disease control rate of mCRC patients,improve the level of tumor markers,and down-regulate the levels of serum VEGF,COX-2,MMP-9,APE1 protein and S100A9,without increasing the risk of toxic side effects,and prolong the median survival time.
Metastatic colorectal cancerBevacizumabMFOLFOX6 planTumor cell apoptosis indexThe lifetimeToxic side effects
NETL
NSTL
万方数据
